ADVERTISEMENT
The FDA just shot down a new rheumatoid arthritis drug (INCY, LLY)
On Friday, pharmaceutical companies Lilly and Incyte said that their drug, baricitinib, had been issued a complete response letter.
A hand of someone who has rheumatoid arthritis.
Pharmaceutical companies Lilly and Incyte said on Friday that their drug, baricitinib, had been issued a complete response letter, which explains why the drug didn't get approval.
In its letter, the FDA told Lilly and Incyte that it wanted more data on what the right dose for the drug is. The FDA also wants more data about potential safety issues.
The FDA had previously pushed back its review date of baricitinib by three months.
JOIN OUR PULSE COMMUNITY!
ADVERTISEMENT
Eyewitness? Submit your stories now via social or:
Email: eyewitness@pulse.ng
ADVERTISEMENT